Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia

Jaspal Kaeda; Frauke Ringel; Christian Oberender; Ken Mills; Concetta Quintarelli; Fabrizio Pane; Steffen Koschmieder; Robert Slany; Rolf Schwarzer; Giuseppe Saglio; Philipp Hemmati; Antje van Lessen; Leila Amini; Martin Greese; Elisabetta Vagge; Thomas Burmeister; Anna Serra; Anne Carson; Michaela Schwarz; Jörg Westermann; Franziska Jundt; Bernd Dörken; Philipp le Coutre

doi:10.3109/10428194.2014.981175

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia

Jaspal Kaeda, Frauke Ringel, Christian Oberender, Ken Mills, Concetta Quintarelli, Fabrizio Pane, Steffen Koschmieder, Robert Slany, Rolf Schwarzer, Giuseppe Saglio, Philipp Hemmati, Antje van Lessen, Leila Amini, Martin Greese, Elisabetta Vagge, Thomas Burmeister, Anna Serra, Anne Carson, Michaela Schwarz, Jörg WestermannFranziska Jundt, Bernd Dörken, Philipp le Coutre

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

Abstract

A better understanding of events triggering chronic myeloid leukemia progression are critical to optimised clinical management of chronic myeloid leukemia (CML). We sought to validate that increased Musashi 2 (MSI2), a post transcription regulator, expression is associated with progression and prognosis. Screening of 152 CML patients showed MSI2 was significantly decreased among CML patients in CP at diagnosis (p<0.0001), but found no significant difference between the normal control group and treated CML patients in CP. Moreover it was significantly increased (p<0.0001) in advance disease (AD) CML patients. Furthermore, our human hematopoietic cell line data imply MSI2 and BCR-ABL1 mRNA expression correlate. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.

Original language	English
Pages (from-to)	2105-2113
Journal	Leukemia & lymphoma
Volume	56
Issue number	7
Early online date	17 Jul 2015
DOIs	https://doi.org/10.3109/10428194.2014.981175
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428194.2014.981175

Cite this

Kaeda, J., Ringel, F., Oberender, C., Mills, K., Quintarelli, C., Pane, F., Koschmieder, S., Slany, R., Schwarzer, R., Saglio, G., Hemmati, P., van Lessen, A., Amini, L., Greese, M., Vagge, E., Burmeister, T., Serra, A., Carson, A., Schwarz, M., ... le Coutre, P. (2015). Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. Leukemia & lymphoma, 56(7), 2105-2113. https://doi.org/10.3109/10428194.2014.981175

@article{7d6cc15e584d49169e07f783c934c633,

title = "Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia",

abstract = "A better understanding of events triggering chronic myeloid leukemia progression are critical to optimised clinical management of chronic myeloid leukemia (CML). We sought to validate that increased Musashi 2 (MSI2), a post transcription regulator, expression is associated with progression and prognosis. Screening of 152 CML patients showed MSI2 was significantly decreased among CML patients in CP at diagnosis (p<0.0001), but found no significant difference between the normal control group and treated CML patients in CP. Moreover it was significantly increased (p<0.0001) in advance disease (AD) CML patients. Furthermore, our human hematopoietic cell line data imply MSI2 and BCR-ABL1 mRNA expression correlate. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.",

author = "Jaspal Kaeda and Frauke Ringel and Christian Oberender and Ken Mills and Concetta Quintarelli and Fabrizio Pane and Steffen Koschmieder and Robert Slany and Rolf Schwarzer and Giuseppe Saglio and Philipp Hemmati and {van Lessen}, Antje and Leila Amini and Martin Greese and Elisabetta Vagge and Thomas Burmeister and Anna Serra and Anne Carson and Michaela Schwarz and J{\"o}rg Westermann and Franziska Jundt and Bernd D{\"o}rken and {le Coutre}, Philipp",

year = "2015",

doi = "10.3109/10428194.2014.981175",

language = "English",

volume = "56",

pages = "2105--2113",

journal = "Leukemia & lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "7",

}

Kaeda, J, Ringel, F, Oberender, C, Mills, K, Quintarelli, C, Pane, F, Koschmieder, S, Slany, R, Schwarzer, R, Saglio, G, Hemmati, P, van Lessen, A, Amini, L, Greese, M, Vagge, E, Burmeister, T, Serra, A, Carson, A, Schwarz, M, Westermann, J, Jundt, F, Dörken, B & le Coutre, P 2015, 'Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia', Leukemia & lymphoma, vol. 56, no. 7, pp. 2105-2113. https://doi.org/10.3109/10428194.2014.981175

TY - JOUR

T1 - Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia

AU - Kaeda, Jaspal

AU - Ringel, Frauke

AU - Oberender, Christian

AU - Mills, Ken

AU - Quintarelli, Concetta

AU - Pane, Fabrizio

AU - Koschmieder, Steffen

AU - Slany, Robert

AU - Schwarzer, Rolf

AU - Saglio, Giuseppe

AU - Hemmati, Philipp

AU - van Lessen, Antje

AU - Amini, Leila

AU - Greese, Martin

AU - Vagge, Elisabetta

AU - Burmeister, Thomas

AU - Serra, Anna

AU - Carson, Anne

AU - Schwarz, Michaela

AU - Westermann, Jörg

AU - Jundt, Franziska

AU - Dörken, Bernd

AU - le Coutre, Philipp

PY - 2015

Y1 - 2015

N2 - A better understanding of events triggering chronic myeloid leukemia progression are critical to optimised clinical management of chronic myeloid leukemia (CML). We sought to validate that increased Musashi 2 (MSI2), a post transcription regulator, expression is associated with progression and prognosis. Screening of 152 CML patients showed MSI2 was significantly decreased among CML patients in CP at diagnosis (p<0.0001), but found no significant difference between the normal control group and treated CML patients in CP. Moreover it was significantly increased (p<0.0001) in advance disease (AD) CML patients. Furthermore, our human hematopoietic cell line data imply MSI2 and BCR-ABL1 mRNA expression correlate. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.

AB - A better understanding of events triggering chronic myeloid leukemia progression are critical to optimised clinical management of chronic myeloid leukemia (CML). We sought to validate that increased Musashi 2 (MSI2), a post transcription regulator, expression is associated with progression and prognosis. Screening of 152 CML patients showed MSI2 was significantly decreased among CML patients in CP at diagnosis (p<0.0001), but found no significant difference between the normal control group and treated CML patients in CP. Moreover it was significantly increased (p<0.0001) in advance disease (AD) CML patients. Furthermore, our human hematopoietic cell line data imply MSI2 and BCR-ABL1 mRNA expression correlate. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.

U2 - 10.3109/10428194.2014.981175

DO - 10.3109/10428194.2014.981175

M3 - Article

C2 - 25363400

SN - 1042-8194

VL - 56

SP - 2105

EP - 2113

JO - Leukemia & lymphoma

JF - Leukemia & lymphoma

IS - 7

ER -

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this